000 03586nam a22004575i 4500
001 vtls000540725
003 RU-ToGU
005 20210922081825.0
007 cr nn 008mamaa
008 160915s2014 xxk| s |||| 0|eng d
020 _a9781447165033
_9978-1-4471-6503-3
024 7 _a10.1007/978-1-4471-6503-3
_2doi
035 _ato000540725
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC346-429.2
072 7 _aMJN
_2bicssc
072 7 _aMED056000
_2bisacsh
082 0 4 _a616.8
_223
245 1 0 _aLevodopa-Induced Dyskinesia in Parkinson's Disease
_helectronic resource
_cedited by Susan H. Fox, Jonathan M. Brotchie.
260 _aLondon :
_bSpringer London :
_bImprint: Springer,
_c2014.
300 _aXII, 368 p. 12 illus., 11 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aPhenomenology of Levodopa-Induced Dyskinesia -- Dyskinesia Rating Scales in Parkinson's Disease -- Epidemiology of Levodopa-Induced Dyskinesia -- Risk Factors for Levodopa-Induced Dyskinesia -- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia -- Surgical Options for Levodopa-Induced Dyskinesia in Parkinson’s Disease -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Pharmacological Properties of Levodopa -- Dopamine Receptors and LID -- The Serotonergic System In Levodopa-Induced Dyskinesia -- The Opioid System in Levodopa-Induced Dyskinesia -- Glutamate Receptors and Levodopa-Induced Dyskinesia -- Cannabinoids and Levodopa-Induced Dyskinesia -- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia -- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia -- New Clinical Trials for Levodopa-Induced Dyskinesia -- Preclinical Models of Levodopa-Induced Dyskinesia -- Final Thoughts: Summary and Future Therapeutic Strategies in LID.
520 _aThis book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside’. Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; ongoing RCTs in LID; and evidence-based medicine reviews of treatment options.  Levodopa-Induced Dyskinesia in Parkinson’s Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees; and graduate and post-graduate students.
650 0 _amedicine.
_9566220
650 0 _aNeurosciences.
_9302217
650 0 _aNeurology.
_9303067
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aNeurology.
_9303067
650 2 4 _aNeurosciences.
_9302217
700 1 _aFox, Susan H.
_eeditor.
_9445367
700 1 _aBrotchie, Jonathan M.
_eeditor.
_9445368
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4471-6503-3
912 _aZDB-2-SME
999 _c398422